



Customer No. 28880

Confirmation No. 6060

PTO/SB/08A (08-03)


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 1449/PTO~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Text
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
XH		CA 2,082,076	11-04-1992	Weidmann, et al		
		EP 0 935 963 A2	08-18-1999	McClure, et al		
		EP 1 138 680 A1	10-04-2001	Noe, et al		
		WO 00/09485	02-24-2000	McClure, et al		
		WO 01/12611 A1	02-22-2001	Julian Blagg		
V		WO 01/63244 A1	08-30-2001	Chen, et al		

Examiner Signature  Date Considered 3/28/2005

EXAMINER: Initial if reference considered.¹ whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional).³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/634,531
				Filing Date	August 5, 2003
				First Named Inventor	Adam R. Johnson
				Art Unit	1624
				Examiner Name	Kahsay Habte
Sheet	2	of	4	Attorney Docket Number	PC25201A

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)		T ⁶	
KH		WO 02/34726 A2	05-02-2002	Noe, et al	
		WO 02/34753 A2	05-02-2002	Bronk, et al	
		WO 01/14344	03-01-2001	Herrmann, et al	
		EP 1069110	01-17-2001	Kimura, et al	
		WO 96/28430	09-19-1996	Nussbaumer	
✓		WO 03/076416	09-18-2003	Gaudilliere, et al	

Examiner Signature		Date Considered	3/27/2005
-----------------------	---	--------------------	-----------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ***Applicant's unique citation designation number (optional).** ***See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.** ***Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).** ***For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** ***Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.** ***Applicant is to place a check mark here if English language Translation is attached.**


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/634,531
Sheet	3	of	4	Filing Date	August 5, 2003
				First Named Inventor	Adam R. Johnson
				Art Unit	1624
				Examiner Name	Kahsay Habte
				Attorney Docket Number	PC25201A

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
KH		Office Action from 10/264,764 mailed 6.16.03			
		Billinghurst, et al, "Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase", Arth. & Rheum. Vol. 43 (3) March 2000, pp. 664-672.			
		Billinghurst, et al, "Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage", J. Clin. Invest., Vol. 99 (7) April 1997 pp.1534-1545.			
		Chen, et al, "Structure-based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., Vol. 122 (40), 2000, pp. 9648-9654.			
		Dahlberg, et al, "Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor That Spares Collagenase 1 (Matrix Metalloproteinase 1)", Arth. & Rheum. Vol. 43 (3), March 2000, pp.673-682.			
		Freement, et al, "In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage" Ann. Rheum. Dis. Vol. 58 1999 pp.357-365.			
		Hirota, et al, "Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyrido[2,3-d]-Pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling", Heterocycles, Vol. 37 (1) 1994 pp. 563-570.			
		Lovejoy, et al, " Crystal structures of MMP-1 and -13 reveal the selectivity of collagenase inhibitors" Nature Structural Bio., Vol 6 (3), March 1999 pp. 217-221.			
		Mitchell, et al, "Cloning, Expression, adn Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage", J. Clin. Invest., Vol. 97 (3), February 1996, pp. 761-768.			
		Moy, et al, "High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor", J. Mol. Bio., Vol. 302, 2000, pp. 671-689.			

Examiner Signature		Date Considered	3/28/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	4	of	4	Attorney Docket Number	PC25201A
-------	---	----	---	------------------------	----------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH		Neuhold, et al, "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice", J. Clin. Invest., Vol. 107 (1), pp. 35-44.	
		Reboul, et al, "The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes", J. Clin. Invest., Vol. 97 (9) May 1996, pp. 2011-2019.	
		Wernicke, et al, "Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis", J. of Rheum. 1996, Vol. 23 (4), pp. 590-595.	
		"Invitation to Pay Additional Fees" from corresponding PCT International Applic. no. PCT/IB03/03518 (5 pages)	

Examiner Signature		Date Considered	3/28/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.